EXPANDED IN Q4
•Here’s hoping that red ink is erasable.
The US economy actually grew in the
fourth quarter of 2012—but just barely—
instead of contracting for the first time in
three and a half years, according to the
The US expanded at a 0.1% annual
rate in the last three months of 2012, better
than the initially reported 0.1% drop but
well below the third quarter’s 3.1% pace.
Stronger residential construction and
an improvement in net exports pushed
growth into positive territory. It offset
a bigger decline in government spending than previously suggested as well as
a sharper deceleration in the buildup of
business inventories, according to the
Net Sales Rise 7.4%
At Yankee Candle
•Yankee Holding Corp. and The
Yankee Candle Company, Inc. posted fi-
nancial results for the fourth quarter and
full year ended Dec. 29, 2012.
For the year ended Dec. 29, 2012,
total company net sales increased 7.4%
to $844.2 million. Retail sales rose 9.1%
to $490.2 million and wholesale sales
increased 1.3% to $238.3 million. Sales
in the company’s international segment
jumped 14.2% to $115.7 million.
Rise 7% in 2012
•Novozymes’s 2012 sales rose 7% to
more than $2.0 billion, the company reported. Net profit rose 10% to nearly $360
million. This year, the company expects organic sales growth of 5-8%.
“We delivered strong earnings growth
and record profitability in a year when
organic sales growth was challenged and
came in at 4%—below our ambition,” said
Steen Riisgaard, president and CEO.“With
2012 behind us, we have reviewed our
long-term growth scenarios and decided
to adjust our long-term financial targets.
We are still confident that we can reach
the long-term sales growth target of more
than 10%, although not until 2015.”
Riisgaard reiterated that the compa-
ny’s strategy is unchanged and, under the
leadership of the new president and CEO
Peder Holk Nielsen, Novozymes will con-
tinue to focus on innovation, partnerships
Yankee Candle is banking on several rollouts for another positive year.
In Shaser Bioscience
•Spectrum Brands Holdings, Inc. ac-
quired a 56% interest in Shaser Bioscience,
Inc., a privately-held global technology
company that develops energy-based,
aesthetic dermatological platforms for
home use devices, for $50 million in cash.
According to the company, the transaction provides Spectrum Brands with
exclusive rights to Shaser Bioscience’s
entire range of technology platforms and
establishes Spectrum Brands’ Remington
personal care division as a leader in large
and rapidly growing segments of the
worldwide beauty and skin care retail device market.
Building on a commercial partnership
established in 2008 between Spectrum
Brands and Shaser Bioscience, through
which the companies have jointly developed and brought to market the